United Kingdom · Biotechnology startup
United Kingdom · RQ Biotechnology Ltd.
RQ Biotechnology Ltd.
Funding reportedLast round: Series A
About RQ Biotechnology Ltd.
RQ Biotechnology Ltd.
(RQ Bio) is a UK-based biotechnology company founded in 2021 and headquartered in London. The company focuses on the discovery and development of long-acting monoclonal antibodies (LAAbs) aimed at providing protection against severe viral diseases. RQ Bio combines expertise in virus evolution, artificial intelligence, and high-throughput screening to create a pipeline of antiviral therapies. The company's lead product, RQB01, is designed to offer immediate and long-lasting protection against seasonal influenza, particularly for immunocompromised and high-risk individuals. RQ Bio is also engaged in developing therapies for a range of infectious diseases, including polio, rabies, measles, and COVID-19. The company collaborates with academic institutions like the University of Oxford and pharmaceutical partners such as AstraZeneca to advance its research and bring effective therapies to market. RQ Bio's mission is to ensure that vulnerable populations receive the protection they need, even when vaccines are insufficient.
What company datasets say RQ Biotechnology Ltd. raised
Funding, as reported
Funding filed with regulators
RQ Biotechnology Ltd. filed one raise, $1.7M in all. Filings say how much was sold and to how many investors; they never name the investors.
- Dec 2022$1.7MUK share allotment
On 2 portfolio pages
Investors who name them
Each firm lists RQ Biotechnology Ltd. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
health careviral mutation resistanceantibody pipelinemonoclonal antibodiesrsvviral diseaseslong-acting monoclonal antibodiesvaccine limitationsimmunocompromised protectioninfluenza antibodiesvulnerable populationsinfectious disease defenseresilient antibody epitopesantibody development against variable virusesimmunologyviral infection therapies
Built with from their website
Squarespace ECommerceViewport MetaDigital Ocean SpaceswebpackOpenAIPriority HintsReactMicrosoft ExchangeMicrosoft 365 Apps & ServicesMobile Friendly
+8 more
VercelOpen GraphLinkedin Marketing SolutionsNext.jsGoDaddy DomainsMicrosoft Exchange OnlineDigitalOceanMicrosoft 365
- Sector
- Biotechnology
- Industry code
- NAICS 541714, SIC 8731
- Region
- England
- Full record
- Every detail in the company directory
Biotechnology in United Kingdom
Startups like it
Is this your company?
Add your raise, your deck and your story, and put RQ Biotechnology Ltd. in front of investors. Or tell us what we have wrong.